Key Findings To Date

The Inflation Reduction Act (IRA)

  1. The OOP average cost increased in total for all of the MFP medicines that were included in the analysis
  2. The average OOP cost across all nine MFP drugs increased by $23.91, from $74.51 to $98.42.
  3. The average OOP cost for all nine MFP medicines increased by 32%.
  4. The OOP costs increased specifically for seven of the nine medicines with a negotiated MFP
  5. Cost increases ranged from $10.56 to $316.81.
  6. Of the two medicines that did not have OOP increases, one faced new competition from biosimilars that only became available in 2025. All four of the largest PBMs increased OOP costs for six of the seven medicines with cost increases; one medication had OOP increases from only three of these PBMs.

Return to Inflation Reduction Act Overview